Combination of laser photocoagulation and intravitreal bevacizumab (Avastin®) for aggressive zone I retinopathy of prematurity

Chung, Eun Jee; Kim, Ji Hyun; Ahn, Hyun Seok; Koh, Hyoung Jun

doi:10.1007/s00417-007-0661-y

Cited by 154 publications

(88 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mean follow-up duration was 20 ± 4.5 months (range, [12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27]. No eyes developed retinal detachment during the follow-up period.…”

Section: Resultsmentioning

confidence: 99%

Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity

Erol

Çoban

Sarı³

et al. 2015

Arquivos Brasileiros De Oftalmologia

View full text Add to dashboard Cite

Purpose:To compare the efficacy of intravitreal ranibizumab and bevacizumab treatment for type 1 retinopathy of prematurity (ROP). Methods: 36 eyes of 20 patients with type 1 ROP who received anti-vascular endothelial growth factor (anti-VEGF) intravitreal injections between August 2011 and February 2013 were retrospectively evaluated. Fifteen eyes of 8 patients received 0.25 mg ranibizumab (group 1), and 21 eyes of 12 patients received 0.625 mg be vacizumab (group 2). Eyes were examined by indirect ophthalmoscopy on the first day, third day, first week, and first month and as required after injections. Laser photocoagulation was performed in cases with progression of ROP. Results: The mean gestation time was 26.2 ± 2.7 weeks in group 1 patients and 27.1 ± 2.5 weeks in group 2 patients. No statistical difference in the time of gestation was observed between the two groups. The mean follow-up period was 20 ± 4.5 months. Laser photocoagulation was performed in 6 of 15 eyes from group 1 and 2 of 21 eyes from group 2. No eyes developed retinal detachment during the follow-up period. Conclusion: Ranibizumab and bevacizumab showed an efficacy in the treatment of type 1 ROP. The incidence of disease relapse was higher in eyes which received ranibizumab. Further randomized, controlled clinical trials are required to compare the efficacy of ranibizumab and bevacizumab. Keywords

show abstract

Section: Resultsmentioning

confidence: 99%

Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity

Erol

Çoban

Sarı³

et al. 2015

Arquivos Brasileiros De Oftalmologia

View full text Add to dashboard Cite

show abstract

“…One rare yet harmful complication of intravitreal injections is endophthalmitis, which occurs at a rate of 0.019 (10) to 0.54% (11). IVB has been approved as a monotherapy or an adjunctive treatment for ROP (3)(4)(5)(6)(7). The present case is the first to report bacterial endophthalmitis in an infant with ROP after treatment with IVB.…”

Section: Introductionmentioning

confidence: 66%

“…Peripheral retinal ablation with confluent laser therapy is the conventional treatment for type I pre-threshold or threshold ROP; however, this approach is invasive, destructive and is not completely effective against blindness in infants. In contrast, anti-vascular endothelial growth factor (VEGF) drugs have emerged as an alternative therapy with positive outcomes (3)(4)(5)(6)(7). Intravitreal injection of bevacizumab (IVB; Avastin ® ), a humanized anti-VEGF monoclonal antibody, is an effective and safe therapy for ROP with no major side effects (3)(4)(5)(6)(7).…”

Section: Introductionmentioning

confidence: 99%

“…In contrast, anti-vascular endothelial growth factor (VEGF) drugs have emerged as an alternative therapy with positive outcomes (3)(4)(5)(6)(7). Intravitreal injection of bevacizumab (IVB; Avastin ® ), a humanized anti-VEGF monoclonal antibody, is an effective and safe therapy for ROP with no major side effects (3)(4)(5)(6)(7). IVB is commonly used to treat diseases, including choroidal neovascularization, proliferative diabetic retinopathy and cystoid macular edema due to retinal vein occlusions (8).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Early clinical characteristics of bacterial endophthalmitis in retinopathy of prematurity after intravitreal bevacizumab injection: A case report

Wang

Xiang

2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Intravitreal bevacizumab injection (IVB) is emerging as a safe and effective therapy for retinopathy of prematurity (ROP); however, follow-up investigations after IVB have indicated that endophthalmitis, a rare and devastating complication, may develop. The present study reports a case of an infant with ROP who developed endophthalmitis after IVB infection. The infant was administered with an intravitreal injection of broad-spectrum antibiotics to treat the endophthalmitis. A favorable anatomic outcome was achieved after follow-up. From this case, it was discovered that the early clinical characteristics of endophthalmitis infection secondary to IVB in premature infants include: i) The clinical symptoms of endophthalmitis infection appearing as early as 3-5 days after IVB; ii) a white membranous plaque on the retina surface with an obscure circular boundary; iii) a plaque that enlarges to a gray flocculent mass and intrudes the vitreous body, where the hazing surrounds the lesion; and iv) conjunctival hyperemia and cornea edema in the anterior segment of the affected eye. This case also indicated that timely retinal screening with RetCam or a binocular ophthalmoscope 3-5 days after IVB may be effective for detecting early stage endophthalmitis in infants who are unable to complain of a loss of visual acuity. From the present case report, it is advisable that the same type of screening be performed 3-5 days after other types of eye surgery, such as cataract extraction surgery, to detect early stage endophthalmitis. Furthermore, the present case also revealed that an early intravitreal injection of broad-spectrum antibiotics may be an effective treatment for premature infants with bacterial endophthalmitis.

show abstract

“…This technique has been performed either alone or in combination with laser photocoagulation of the peripheral avascular retina. [1][2][3] All the case reports used intravitreal bevacizumab (Avastin, Genentech, South San Francisco, CA, USA), with the dosage varying from 0.4 to 1.25 mg per injection, and the results have been remarkable. Regression of plus disease and neovascularization is usually observed within 1 week after treatment.…”

Section: Introductionmentioning

confidence: 99%

Choroidal ruptures after adjuvant intravitreal injection of bevacizumab for aggressive posterior retinopathy of prematurity

Trinavarat

2010

J Perinatol

View full text Add to dashboard Cite

In recent times, laser treatment combined with intravitreal bevacizumab (Avastin) has been used rarely as early investigations to treat patients with aggressive posterior retinopathy of prematurity (ROP). We describe choroidal ruptures that were documented at 10 weeks after this combined treatment in a preterm infant born at 28 weeks gestation with a birth weight of 1190 g. Aggressive posterior ROP was diagnosed at the age of 6 weeks. Initial treatment included bilateral laser ablation, followed immediately by intravitreal bevacizumab (IVB, 0.75 mg) in the right eye. On day 5, a remarkable regression of plus sign and fibrovascular proliferation was noted only in the right eye. At this point, additional laser treatment combined with IVB was given in the left eye, which dramatically resolved plus disease and neovascularization. At 10 weeks after IVB in the left eye, two sites of choroidal ruptures were revealed along the posterior edges of laser scars. There was no evidence of choroidal neovascularization associated with the choroidal ruptures. Choroidal rupture may occur shortly after laser ablation plus IVB treatment for aggressive posterior ROP. This occurrence requires recognition to determine whether it is actually related to the treatment. Long-term follow-up is important for understanding the nature and progression of this potentially serious complication.

show abstract

Combination of laser photocoagulation and intravitreal bevacizumab (Avastin®) for aggressive zone I retinopathy of prematurity

Abstract: The combination of indirect laser photocoagulation and intravitreal bevacizumab injection was well tolerated and induced prompt regression of aggressive zone I ROP.

Cited by 154 publications

References 24 publications

Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity

Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity

Early clinical characteristics of bacterial endophthalmitis in retinopathy of prematurity after intravitreal bevacizumab injection: A case report

Choroidal ruptures after adjuvant intravitreal injection of bevacizumab for aggressive posterior retinopathy of prematurity

Contact Info

Product

Resources

About